← Back to Screener
TherapeuticsMD, Inc. (TXMD)
Price$1.99
Value ScoreB
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)9.13%
Price vs S&P 500 (4W)0.51%
VGM Score59.29
Market Capitalization$23.03M
All Metrics
P/CF (Annual)9.50x
Book Value / Share (Quarterly)$2.33
P/TBV (Annual)0.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-64.91%
Cash Flow / Share (Quarterly)$0.23
Price vs S&P 500 (YTD)13.93%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)5.34%
EPS (TTM)$0.02
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$0.02
Revenue Growth (5Y)-45.84%
EPS (Annual)$-0.05
ROI (Annual)-2.12%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-1496.19%
Cash / Share (Quarterly)$0.73
P/E Basic Excl Extra (TTM)128.67x
Revenue Growth QoQ (YoY)84.22%
ROA (Last FY)-1.51%
Revenue Growth TTM (YoY)82.13%
EBITD / Share (TTM)$-0.30
ROE (5Y Avg)-328.15%
Operating Margin (TTM)-114.29%
Cash Flow / Share (Annual)$0.21
P/B Ratio0.85x
P/B Ratio (Quarterly)0.87x
Net Income / Employee (Annual)$-569,000
EV / Revenue (TTM)4.36x
Net Interest Coverage (TTM)-5.42x
ROA (TTM)0.47%
EV / EBITDA (TTM)0.24x
EPS Incl Extra (Annual)$-0.05
Current Ratio (Annual)3.02x
Quick Ratio (Quarterly)2.59x
3-Month Avg Trading Volume0.03M
52-Week Price Return79.28%
EV / Free Cash Flow (Annual)6.03x
P/E Incl Extra (TTM)128.67x
Revenue / Employee (TTM)$3,353,000
Tangible BV / Share (Quarterly)$2.01
P/S Ratio (Annual)7.62x
Asset Turnover (Annual)0.08x
52-Week High$2.95
Operating Margin (5Y Avg)-848.35%
EPS Excl Extra (Annual)$-0.05
Tangible BV CAGR (5Y)-28.85%
26-Week Price Return17.06%
Quick Ratio (Annual)2.51x
13-Week Price Return-10.76%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.11x
Enterprise Value$14.61M
Revenue / Share Growth (5Y)-53.31%
Asset Turnover (TTM)0.09x
Book Value / Share Growth (5Y)-35.19%
Revenue / Employee (Annual)$3,022,000
Inventory Turnover (Annual)1.60x
Pretax Margin (Annual)-21.61%
Cash / Share (Annual)$0.65
3-Month Return Std Dev43.68%
Gross Margin (5Y Avg)81.23%
Net Income / Employee (TTM)$179,000
ROE (Last FY)-2.12%
Net Interest Coverage (Annual)-9.43x
EPS Basic Excl Extra (Annual)$-0.05
P/FCF (TTM)8.61x
Receivables Turnover (TTM)-1.85x
EV / Free Cash Flow (TTM)5.46x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.02
Receivables Turnover (Annual)2.28x
ROI (TTM)0.66%
P/S Ratio (TTM)6.87x
Pretax Margin (5Y Avg)-766.75%
Revenue / Share (Annual)$0.26
Tangible BV / Share (Annual)$2.00
Forward P/E11.71x
Price vs S&P 500 (52W)54.91%
P/E Ratio (TTM)128.67x
Year-to-Date Return22.09%
5-Day Price Return-6.13%
EPS Normalized (Annual)$-0.05
ROA (5Y Avg)-1.76%
Net Profit Margin (Annual)-18.83%
Month-to-Date Return-7.01%
Cash Flow / Share (TTM)$-3.86
EBITD / Share (Annual)$-0.35
Operating Margin (Annual)-145.27%
LT Debt / Equity (Annual)21.15x
P/CF (TTM)8.61x
ROI (5Y Avg)37.50%
P/E Excl Extra (TTM)128.67x
LT Debt / Equity (Quarterly)21.15x
EPS Basic Excl Extra (TTM)$0.02
P/TBV (Quarterly)1.00x
P/B Ratio (Annual)0.70x
Inventory Turnover (TTM)-1.60x
Pretax Margin (TTM)3.52%
Book Value / Share (Annual)$2.32
Price vs S&P 500 (13W)-19.02%
Beta0.65x
P/FCF (Annual)9.50x
Revenue / Share (TTM)$0.29
ROE (TTM)0.66%
52-Week Low$0.98
vGradeB
gGradeC
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Nov 2023
Dec 2023
Jan 2024
Feb 2024
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TXMDTherapeuticsMD, Inc. | B | C | C | $1.99 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
TherapeuticsMD is a pharmaceutical royalty company that generates revenue from women's health products licensed to Mayne Pharma for U.S. commercialization, including IMVEXXY, BIJUVA, ANNOVERA, and prescription prenatal vitamins. By licensing its portfolio to an established pharmaceutical partner, the company collects royalties while minimizing operational expenses.